2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
In Partnership With:
Conference | ASH Annual Meeting and Exposition
Thomas G. Martin, MD, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.
Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California San Francisco (UCSF), co-leader, Cancer Immunology & Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 2-year follow-up data of the phase 1/2 CARTITUDE-1 study (NCT03548207) in relapsed/refractory multiple myeloma, that were presented during the 2021 ASH Annual Meeting & Exposition.
During the meeting, Martin presented the 2-year update of the CARTITUDE-1 study, which evaluated the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory multiple myeloma. The results of the study demonstrated an overall response rate of 97.9% with the therapy, Martin says. Additionally, of the 97 patients enrolled on the trial, 2 patients didn't respond. One was found to have unmeasurable disease at baseline and, therefore, could not be assessed for response, Martin explains. However, this patient is 2 years into remission currently, Martin adds.
The 18-month progression-free survival (PFS) rate 60.5% with cilta-cel and a median PFS was still not reached with 2 years of follow-up, Martin continued. Moreover, the rate of stringent complete responses haveincreased with cilta-cel from 67% at the 1-year analysis to 82.5% at the 2-year analysis, Martin says. Overall, patients treated with cilta-cel obtained deep and durable responses, which is favorable in this heavily pretreated population, Martin concluded.